Clinical TrialJun 11, 2026, 08:16 AM
Theriva Biologics: VCN-01 Trial Shows Survival Benefit in HNSCC
AI Summary
Theriva Biologics announced that clinical and translational results from its VCN-01 Phase 1 clinical trial in Head & Neck Squamous Cell Carcinoma (HNSCC) were published in Clinical Cancer Research. The trial in 20 refractory HNSCC patients showed median overall survival ranging from 10.3 to 17.3 months across different treatment arms. Biomarker analysis indicated VCN-01's potential to degrade tumor stroma and enhance anti-tumor immune responses, supporting its combination with durvalumab.
Key Highlights
- Median progression-free survival (PFS) was 1.6 months (Arm I LD), 3.7 months (Arm II LD), and 2.1 months (Arm II HD).
- Median overall survival (OS) was 10.3 months (Arm I LD), 15.5 months (Arm II LD), and 17.3 months (Arm II HD).
- Circulating PH20 enzyme levels increased significantly post-VCN-01 administration, peaking on day 3-8.
- VCN-01 viral genome levels in blood showed a secondary peak on day 3-8, consistent with tumor replication.
- Tumor biopsies showed upregulation of CD8 and IDO, implying increased cytotoxic T cell infiltration.
- Tumor biopsies revealed upregulation of PD-1 and PD-L1, correlating with patient survival.
Price Impact
More from TOVX